Viridian promotes Tom Ciulla to CMO; details 2024 TED trial timelines and FcRn milestones

Viridian Therapeutics, Inc.\DE

Dr. Thomas Ciulla promoted to CMO, succeeding Dr. Barrett Katz who becomes consultant; Dr. Katz receives severance and consulting fee.
Topline results from THRIVE Phase 3 (active TED) expected mid-2024; THRIVE-2 (chronic TED) by year-end 2024.
Subcutaneous VRDN-003 pivotal study expected to start mid-2024 pending regulatory alignment.
FcRn portfolio: VRDN-006 IND by year-end 2024; VRDN-008 NHP data in 2H 2024.
Inducement grant of 62,000 stock options to new employee outside equity plan.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Thomas Ciulla

Chief Medical Officer

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2024-01-03
Filed: January 8, 2024, 6:59 PM ET

The Board of Directors of the Company appointed Dr. Thomas Ciulla, formerly the Company’s Chief Development Officer since February 2023, as Chief Medical Officer of the Company effective January 3, 2024.

Departed

Dr. Barrett Katz

Chief Medical Officer

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2024-01-03
Successor: Dr. Thomas Ciulla
Filed: January 8, 2024, 6:59 PM ET

On January 3, 2024, after discussions with Viridian Therapeutics, Inc. (the “Company”) regarding his future plans, Dr. Barrett Katz, age 74, transitioned to a consulting role and ceased to serve as Chief Medical Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Thomas Ciulla was appointed as Chief Medical Officer at Viridian Therapeutics, Inc.\DE.

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

The Board of Directors of the Company appointed Dr. Thomas Ciulla, formerly the Company’s Chief Development Officer since February 2023, as Chief Medical Officer of the Company effective January 3, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Barrett Katz departed as Chief Medical Officer at Viridian Therapeutics, Inc.\DE.

Action: ceased to serve
Role: Chief Medical Officer

Exact text from the filing

On January 3, 2024, after discussions with Viridian Therapeutics, Inc. (the “Company”) regarding his future plans, Dr. Barrett Katz, age 74, transitioned to a consulting role and ceased to serve as Chief Medical Officer of the Company.

View on SEC.gov

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-24-003936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.